The FDA has approved Viridian Therapeutics' veligrotug, branded as Lumvoa, for thyroid eye disease — ending Amgen's Tepezza's solo run as the only approved therapy since 2020. Thyroid eye disease, an autoimmune condition causing painful eye bulging, double vision, and potential vision loss, has been a one-drug monopoly. CEO Steve Mahoney said Lumvoa will be priced "in line with" Tepezza, setting up a direct head-to-head pricing battle from day one. For...